



*A Personalized Healthcare Services  
and Technology Provider*

**INVESTOR PRESENTATION**

**JULY 2022**

**OTCQB: RXMD**

**Forward-Looking Statements** - This presentation contains forward-looking statements about our business. These forward-looking statements do not relate strictly to historical or current facts. Forward-looking statements involve risks and uncertainties and include statements regarding, among other things, our projected revenue growth and profitability, our growth strategies and opportunity, anticipated trends in our market and our anticipated needs for working capital. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “anticipate,” “estimate,” “plans,” “potential,” “projects,” “continuing,” “ongoing,” “expects,” “management believes,” “we believe,” “we intend” or the negative of these words or other variations on these words or comparable terminology. You should not put undue reliance on these forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those reflected in such statements including: risks associated with current and potential future healthcare reforms; risks relating to technology failures or breaches; aspects of our business which are outside, risks relating to management and key personnel changes including attracting and retaining key personnel; failure to comply with legal and regulatory requirements; risks relating to access to capital and credit markets; risks related to indebtedness; exposure to claims and liabilities; changes in industry pricing benchmarks; and other risks and uncertainties that are described in the Risk Factors section of our recently filed Form 10-12G, including the presentation of financial statements and notes thereto, and other reports we have filed with the U.S. Securities and Exchange Commission. These reports are available at [www.sec.gov](http://www.sec.gov) or by calling our Investor Relations department at (888) 919-7411. Forward-looking statements speak only as of the date they are posted to this website, unless an earlier date is indicated, and we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

**Non-GAAP Financial Measures** – This presentation includes certain “non-GAAP financial measures” as defined in Regulation G under the Securities Exchange Act of 1934. Schedules are attached that reconcile the non-GAAP financial measures included in this presentation to the most directly comparable financial measures calculated and presented in accordance with Generally Accepted Accounting Principles in the United States. You should carefully read Progressive Care’s periodic and current filings on the OTC Markets website for definitions and further explanation and disclosure regarding our use of non-GAAP financial measures and such filings should be read in conjunction with this presentation.



# Who we are

**Progressive Care Inc.** (OTCQB: **RXMD**), through its subsidiaries, is a **Florida healthcare technology organization** and provider of prescription pharmaceuticals, compounded and anti-retroviral medications, the supplier of prescription medications to long-term care facilities, provider of medication therapy management (MTM), remote therapy management, COVID-19 testing and immunizations, tele-pharmacy services, third-party administration management and reporting and health practice risk management.

Financial Data (Year ended 12/31/2021)

**\$38.9M**

2021 Revenue

**26%**

Gross Margin

**\$0.2M**

EBITDA



# 2021 Summary

## Key Financial Highlights for Year Ended December 31, 2021

- Revenue at \$38.9 million
- Gross margin increased to 26% in 2021, from 23% in 2020
- EBITDA increased to \$167,000 in 2021 from \$7,000 in 2020
- Cash balance of \$1.4 million as of December 31, 2021

## Q4 2021 Reflected a Strong Bounce Back in Business

- Increase of 10% in prescription revenue to \$8.9 million in the fourth quarter of 2021, from \$8.1 million in the third quarter of 2021
- Increase of 8% in prescriptions filled to 114,000 in the fourth quarter of 2021, from 106,000 in the third quarter of 2021

## Subsequent Events

- Filed Form 10-12G registration statement with the SEC



# Our mission

At Progressive Care, our mission is to improve every step of the patient journey by adding value to prescribers, caregivers, and patients in a seamless manner. Through the implementation of proven processes, we empower medical practices to achieve the highest standards of personalized care.

We enable medical practices achieve high performance scores with payors through our robust pharmacy and reporting platform improving adherence while managing costs.







# Areas of Operation

- Prescription pharmaceuticals
- Contracted pharmacy services for 340B covered entities
- Data Management and analytics
- Health practice risk management
- Anti-retroviral medications
- Medication therapy management
- Supply of prescription medications to long-term care facilities
- Compound medications
- Third Party administration services
- Developing SaaS capabilities
- Tele-pharmacy services



# PharmcoRx Pharmacy

PharmcoRx has worked to uphold the philosophy that our singular goal is to improve and preserve the well-being of our patients, their families, and the community.

Today, this mission has grown to include improving the healthcare system, as a whole, by providing a complete and accountable cycle of care. We strive to successfully connect patients and caregivers with the health care providers and payors to achieve the absolute best health outcomes for each and every individual.



Current pharmacy statistics

**20.5K**

Patients serviced in 2021

**6.7K**

Prescribers serviced in 2021

**443K**

Prescriptions filled in 2021



# Licensed in 13 states with capabilities to go nationwide





# ClearMetrX



ClearMetrX provides data management and third party administration, or TPA, services for 340B Covered Entities, pharmacy analytics, and programs to manage measures such as Medication Adherence.

It came to fulfill the need for frontline providers to understand best practices, patient behaviors, care management processes, and the financial mechanisms behind these decisions. Providing data access and delivering actionable insights to providers and support organizations to improve their practice performance and patient care.



## ClearMetrX TPA and 340B Statistics

**\$900K**


Total TPA fees in 2021

**\$19M**

Total 340B billings

# COVID-19 Response

- Strong presence as a leading Covid-19 testing center in South and Central Florida
- Generated \$4.3 million in testing revenues during 2021, a \$3.7 million increase
- Will continue to build ourselves as a dependable destination for rapid testing solutions
- Certified vendor with major media production companies including Paramount Global (former ViacomCBS), Netflix, Bravo, Amazon, Universal Music, and many others.
- Plans for future expansion into other rapid testing areas like STD's and drug detection.



## Current COVID-19 statistics

**60 min**

Average waiting time for  
COVID-19 PCR results

**34K**

Approx. tests performed since the  
start of COVID-19 pandemic

**\$4.3M**

Testing revenue in 2021





# Quick Links

- ➔ [Progressive Care Reports Full Year 2021 Financial Results Highlighted by \\$38.9 Million in Revenue \(press release\)](#)
- ➔ [Progressive Care Annual Report For Fiscal Year Ended December 31, 2021 \(AUDITED\)](#)
- ➔ [Our stock](#)
- ➔ [PharmcoRx Pharmacy website](#)
- ➔ [ClearMetrX website](#)
- ➔ [Our team](#)
- ➔ [Our board of directors](#)

# Thank you.



**Progressive Care, Inc.**  
400 Ansin Blvd. Suite A  
Hallandale Beach, FL 33009



[Progressivecareus.com](http://Progressivecareus.com)



[Visit our LinkedIn](#)



[Visit our Twitter](#)



[Visit our StockTwits](#)

**Investor Relations:**  
**ClearThink Capital**  
[nyc@clearthink.capital](mailto:nyc@clearthink.capital)  
**P917-658-7878**

**Public Relations:**  
**Carlos Rangel**  
[carlosr@pharmcorx.com](mailto:carlosr@pharmcorx.com)